NCT05831995 - Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Advanced Solid TumorRAS MutationRAF MutationNF1 Mutation

Interventions

DRUG

ABM-168

Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration

Trial Locations (6)

Indiana University Simon and Bren Simon Comprehensive Cancer Center, Indianapolis

Next Oncology, Irving

MD Anderson Cancer Center, Houston

Huntsman Cancer Institute, University of Utah, Salt Lake City

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Rutgers Cancer Institute of New Jersey, New Brunswick